344 related articles for article (PubMed ID: 30279030)
1. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis.
Chang KV; Chen JD; Wu WT; Huang KC; Lin HY; Han DS
J Formos Med Assoc; 2019 Apr; 118(4):833-842. PubMed ID: 30279030
[TBL] [Abstract][Full Text] [Related]
2. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.
Bhanji RA; Moctezuma-Velazquez C; Duarte-Rojo A; Ebadi M; Ghosh S; Rose C; Montano-Loza AJ
Hepatol Int; 2018 Jul; 12(4):377-386. PubMed ID: 29881992
[TBL] [Abstract][Full Text] [Related]
3. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement.
Nardelli S; Lattanzi B; Torrisi S; Greco F; Farcomeni A; Gioia S; Merli M; Riggio O
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):934-936. PubMed ID: 27816756
[TBL] [Abstract][Full Text] [Related]
4. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS.
Gioia S; Merli M; Nardelli S; Lattanzi B; Pitocchi F; Ridola L; Riggio O
Liver Int; 2019 May; 39(5):871-877. PubMed ID: 30667572
[TBL] [Abstract][Full Text] [Related]
5. The Role of Sarcopenia and Frailty in Hepatic Encephalopathy Management.
Lucero C; Verna EC
Clin Liver Dis; 2015 Aug; 19(3):507-28. PubMed ID: 26195205
[TBL] [Abstract][Full Text] [Related]
6. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease.
Lattanzi B; Nardelli S; Pigliacelli A; Di Cola S; Farcomeni A; D'Ambrosio D; Gioia S; Ginanni Corradini S; Lucidi C; Mennini G; Rossi M; Merli M; Riggio O
Dig Liver Dis; 2019 Nov; 51(11):1508-1512. PubMed ID: 31601536
[TBL] [Abstract][Full Text] [Related]
7. Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis.
Nardelli S; Lattanzi B; Merli M; Farcomeni A; Gioia S; Ridola L; Riggio O
Hepatology; 2019 Nov; 70(5):1704-1713. PubMed ID: 31038758
[TBL] [Abstract][Full Text] [Related]
8. Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis.
Wijarnpreecha K; Werlang M; Panjawatanan P; Kroner PT; Cheungpasitporn W; Lukens FJ; Pungpapong S; Ungprasert P
Ann Hepatol; 2020; 19(3):245-250. PubMed ID: 31422030
[TBL] [Abstract][Full Text] [Related]
9. Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study.
Tateyama M; Naoe H; Tanaka M; Tanaka K; Narahara S; Tokunaga T; Kawasaki T; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Sasaki Y; Tanaka Y
BMC Gastroenterol; 2020 Nov; 20(1):371. PubMed ID: 33167879
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia and cognitive impairment in liver cirrhosis: A viewpoint on the clinical impact of minimal hepatic encephalopathy.
Nardelli S; Gioia S; Faccioli J; Riggio O; Ridola L
World J Gastroenterol; 2019 Sep; 25(35):5257-5265. PubMed ID: 31558871
[TBL] [Abstract][Full Text] [Related]
11. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis.
Tantai XX; Yang LB; Wei ZC; Xiao CL; Chen LR; Wang JH; Liu N
World J Gastroenterol; 2019 Jun; 25(21):2683-2698. PubMed ID: 31210719
[TBL] [Abstract][Full Text] [Related]
12. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study.
Merli M; Giusto M; Lucidi C; Giannelli V; Pentassuglio I; Di Gregorio V; Lattanzi B; Riggio O
Metab Brain Dis; 2013 Jun; 28(2):281-4. PubMed ID: 23224378
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of skeletal muscle abnormalities in patients with cirrhosis.
Ebadi M; Montano-Loza AJ
Dig Liver Dis; 2019 Nov; 51(11):1493-1499. PubMed ID: 31221549
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenia: Ammonia metabolism and hepatic encephalopathy.
Jindal A; Jagdish RK
Clin Mol Hepatol; 2019 Sep; 25(3):270-279. PubMed ID: 31006226
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of and associated factors for sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis.
Tuo S; Yeo YH; Chang R; Wen Z; Ran Q; Yang L; Fan Q; Kang J; Si J; Liu Y; Shi H; Li Y; Yuan J; Liu N; Dai S; Guo X; Wang J; Ji F; Tantai X
Clin Nutr; 2024 Jan; 43(1):84-94. PubMed ID: 38016243
[TBL] [Abstract][Full Text] [Related]
16. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis.
Tantai X; Liu Y; Yeo YH; Praktiknjo M; Mauro E; Hamaguchi Y; Engelmann C; Zhang P; Jeong JY; van Vugt JLA; Xiao H; Deng H; Gao X; Ye Q; Zhang J; Yang L; Cai Y; Liu Y; Liu N; Li Z; Han T; Kaido T; Sohn JH; Strassburg C; Berg T; Trebicka J; Hsu YC; IJzermans JNM; Wang J; Su GL; Ji F; Nguyen MH
J Hepatol; 2022 Mar; 76(3):588-599. PubMed ID: 34785325
[TBL] [Abstract][Full Text] [Related]
17. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.
Kumar A; Davuluri G; Silva RNE; Engelen MPKJ; Ten Have GAM; Prayson R; Deutz NEP; Dasarathy S
Hepatology; 2017 Jun; 65(6):2045-2058. PubMed ID: 28195332
[TBL] [Abstract][Full Text] [Related]
18. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
Butterworth RF
Can J Gastroenterol Hepatol; 2019; 2019():8182195. PubMed ID: 31183339
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of sarcopenia assessment in patients with liver cirrhosis.
Marasco G; Dajti E; Ravaioli F; Brocchi S; Rossini B; Alemanni LV; Peta G; Bartalena L; Golfieri R; Festi D; Colecchia A; Renzulli M
Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):377-388. PubMed ID: 33196344
[No Abstract] [Full Text] [Related]
20. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Bai M; Yang Z; Qi X; Fan D; Han G
J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
